Royal Bank of Canada Invests $47.46 Million in Cantel Medical Corp. (CMD) Stock
Royal Bank of Canada purchased a new position in Cantel Medical Corp. (NYSE:CMD) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 609,114 shares of the company’s stock, valued at approximately $47,456,000. Royal Bank of Canada owned 1.47% of Cantel Medical Corp. as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of CMD. BlackRock Inc. bought a new position in Cantel Medical Corp. in the 2nd quarter worth approximately $376,271,000. Vanguard Group Inc. bought a new position in Cantel Medical Corp. in the 2nd quarter worth approximately $246,860,000. Neuberger Berman Group LLC bought a new position in Cantel Medical Corp. in the 2nd quarter worth approximately $96,236,000. Dimensional Fund Advisors LP bought a new position in Cantel Medical Corp. in the 2nd quarter worth approximately $75,756,000. Finally, Wells Fargo & Company MN bought a new position in Cantel Medical Corp. in the 2nd quarter worth approximately $75,715,000. 83.79% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/06/royal-bank-of-canada-invests-47-46-million-in-cantel-medical-corp-cmd-stock.html.
In other Cantel Medical Corp. news, Director Mark N. Diker sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $98.90, for a total value of $692,300.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Charles M. Diker sold 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $75.52, for a total value of $2,643,200.00. Following the completion of the sale, the chairman now owns 3,114,520 shares in the company, valued at approximately $235,208,550.40. The disclosure for this sale can be found here. Insiders sold 62,500 shares of company stock worth $5,368,075 in the last 90 days. Corporate insiders own 14.90% of the company’s stock.
Several brokerages have commented on CMD. Zacks Investment Research raised Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Sidoti raised Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research report on Wednesday, August 2nd. Benchmark Co. downgraded Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical Corp. in a research report on Thursday, June 8th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Cantel Medical Corp. currently has a consensus rating of “Hold” and a consensus target price of $91.67.
Cantel Medical Corp. (NYSE:CMD) opened at 97.82 on Friday. The firm has a 50-day moving average price of $84.24 and a 200 day moving average price of $77.67. The company has a market capitalization of $4.06 billion, a P/E ratio of 57.20 and a beta of 1.25. Cantel Medical Corp. has a 12 month low of $68.19 and a 12 month high of $99.83.
Cantel Medical Corp. (NYSE:CMD) last released its quarterly earnings data on Thursday, September 28th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.02. The firm had revenue of $205.50 million for the quarter, compared to analyst estimates of $200.32 million. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. Analysts expect that Cantel Medical Corp. will post $2.34 EPS for the current year.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Want to see what other hedge funds are holding CMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMD).
Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.